Annual Report

Overview

The report describes the company's FY26 strategic shift toward Female Testosterone MDTS, supported by monetisation of existing assets and a core income stream from topical generic products. It reports revenue growth of 46% to $6.596 million, including product-agreement income, licensing income, and RDTI revenue. The ESG section outlines commitments to reducing energy use and waste, safe and ethical operations, employee wellbeing, diversity and inclusion, and Board-supported governance practices.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2026
Period: Ends 30 June 2026
Publication date: 26 August 2026
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services